中国医药导报
中國醫藥導報
중국의약도보
CHINA MEDICAL HERALD
2015年
22期
128-131
,共4页
王静%杨宝江%常银竹%徐立彦
王靜%楊寶江%常銀竹%徐立彥
왕정%양보강%상은죽%서립언
加味沙参麦冬汤%咳嗽变异性哮喘%疗效
加味沙參麥鼕湯%咳嗽變異性哮喘%療效
가미사삼맥동탕%해수변이성효천%료효
Modified Shashen Maidong Decoction%Cough variant asthma%Efficacy
目的:观察加味沙参麦冬汤治疗咳嗽变异性哮喘(CVA)的临床效果。方法选择2011年1月~2013年12月北京市房山区中医院收治的CVA发作期患者120例,按照随机数字表法将其分为治疗组和对照组。对照组60例给予孟鲁司特钠片10 mg口服,1次/d,必要时吸入短效激素(布地奈德),2周为1个疗程。治疗组60例在对照组治疗基础上给予加味沙参麦冬汤口服,1剂/d,2次/d,2周为1个疗程。治疗后观察患者主要症状、证候积分情况,测定患者呼气峰流量变异率(PEFR)和血清白细胞介素-2(IL-2)、白细胞介素-6(IL-6)和肿瘤坏死因子-α(TNF-α)的含量。结果1个疗程后,治疗组与对照组CVA治疗有效率分别为91.67%和53.33%,差异有高度统计学意义(P<0.01)。单项症状改善方面,咳嗽症状治疗组有效率为95.00%,对照组为63.33%;咽痒症状治疗组有效率为91.67%,对照组为55.00%;气急症状治疗组有效率为98.33%,对照组为55.00%;咳痰症状治疗组有效率为86.67%,对照组为56.67%。两组差异均有统计学意义(均P<0.05)。治疗组治疗后PEFR为(10.41±1.45)%,显著低于对照组[(17.22±2.18)%],差异有统计学意义(P<0.05)。治疗组治疗后IL-2为(12.18±2.28)μg/mL,显著高于对照组[(9.46±1.12)μg/mL],差异有高度统计学意义(P<0.01)。治疗组治疗后IL-6为(43.22±14.29)μg/mL,显著低于对照组[(62.64±15.21)μg/mL],差异有高度统计学意义(P<0.01)。治疗组治疗后TNF-α为(0.59±0.24)μg/mL,显著低于对照组[(0.89±0.23)μg/mL],差异有统计学意义(P<0.05)。结论加味沙参麦冬汤治疗CVA可显著提高疗效,值得临床推广。
目的:觀察加味沙參麥鼕湯治療咳嗽變異性哮喘(CVA)的臨床效果。方法選擇2011年1月~2013年12月北京市房山區中醫院收治的CVA髮作期患者120例,按照隨機數字錶法將其分為治療組和對照組。對照組60例給予孟魯司特鈉片10 mg口服,1次/d,必要時吸入短效激素(佈地奈德),2週為1箇療程。治療組60例在對照組治療基礎上給予加味沙參麥鼕湯口服,1劑/d,2次/d,2週為1箇療程。治療後觀察患者主要癥狀、證候積分情況,測定患者呼氣峰流量變異率(PEFR)和血清白細胞介素-2(IL-2)、白細胞介素-6(IL-6)和腫瘤壞死因子-α(TNF-α)的含量。結果1箇療程後,治療組與對照組CVA治療有效率分彆為91.67%和53.33%,差異有高度統計學意義(P<0.01)。單項癥狀改善方麵,咳嗽癥狀治療組有效率為95.00%,對照組為63.33%;嚥癢癥狀治療組有效率為91.67%,對照組為55.00%;氣急癥狀治療組有效率為98.33%,對照組為55.00%;咳痰癥狀治療組有效率為86.67%,對照組為56.67%。兩組差異均有統計學意義(均P<0.05)。治療組治療後PEFR為(10.41±1.45)%,顯著低于對照組[(17.22±2.18)%],差異有統計學意義(P<0.05)。治療組治療後IL-2為(12.18±2.28)μg/mL,顯著高于對照組[(9.46±1.12)μg/mL],差異有高度統計學意義(P<0.01)。治療組治療後IL-6為(43.22±14.29)μg/mL,顯著低于對照組[(62.64±15.21)μg/mL],差異有高度統計學意義(P<0.01)。治療組治療後TNF-α為(0.59±0.24)μg/mL,顯著低于對照組[(0.89±0.23)μg/mL],差異有統計學意義(P<0.05)。結論加味沙參麥鼕湯治療CVA可顯著提高療效,值得臨床推廣。
목적:관찰가미사삼맥동탕치료해수변이성효천(CVA)적림상효과。방법선택2011년1월~2013년12월북경시방산구중의원수치적CVA발작기환자120례,안조수궤수자표법장기분위치료조화대조조。대조조60례급여맹로사특납편10 mg구복,1차/d,필요시흡입단효격소(포지내덕),2주위1개료정。치료조60례재대조조치료기출상급여가미사삼맥동탕구복,1제/d,2차/d,2주위1개료정。치료후관찰환자주요증상、증후적분정황,측정환자호기봉류량변이솔(PEFR)화혈청백세포개소-2(IL-2)、백세포개소-6(IL-6)화종류배사인자-α(TNF-α)적함량。결과1개료정후,치료조여대조조CVA치료유효솔분별위91.67%화53.33%,차이유고도통계학의의(P<0.01)。단항증상개선방면,해수증상치료조유효솔위95.00%,대조조위63.33%;인양증상치료조유효솔위91.67%,대조조위55.00%;기급증상치료조유효솔위98.33%,대조조위55.00%;해담증상치료조유효솔위86.67%,대조조위56.67%。량조차이균유통계학의의(균P<0.05)。치료조치료후PEFR위(10.41±1.45)%,현저저우대조조[(17.22±2.18)%],차이유통계학의의(P<0.05)。치료조치료후IL-2위(12.18±2.28)μg/mL,현저고우대조조[(9.46±1.12)μg/mL],차이유고도통계학의의(P<0.01)。치료조치료후IL-6위(43.22±14.29)μg/mL,현저저우대조조[(62.64±15.21)μg/mL],차이유고도통계학의의(P<0.01)。치료조치료후TNF-α위(0.59±0.24)μg/mL,현저저우대조조[(0.89±0.23)μg/mL],차이유통계학의의(P<0.05)。결론가미사삼맥동탕치료CVA가현저제고료효,치득림상추엄。
Objective To observe the clinical efficacy of Modified Shashen Maidong Decoction in the treatment of pa-tients with cough variant asthma (CVA). Methods One hundred and twenty cases of patients with CVA at the stage of attack admitted to Fangshan Traditional Medical Hospital of Beijing from January 2011 to December 2013 were select-ed. According to random number table, patients were divided into treatment group and control group. 60 cases of con-trol group were given 10 mg Montelukast Sodium Tablets orally, once a day, a short-acting hormone (Budesonide) was added when necessary, 2 weeks was as a course. 60 cases of treatment group were given Modified Shashen Maidong Decoction on basis of control group, one dose a day, twice a day, 2 weeks was as a course. After treatment, the main symptoms and syndrome scores were observed, the contents of peak expiratory flow rate variability (PEFR), serum in-terleukin-2 (IL-2), interleukin-6 (IL-6) and tumor necrosis factor-α(TNF-α) were detected. Results After a course of treatment, the efficacy rate of treatment group and control group was 91.67%, 53.33%, the difference was highly statis-tically significant (P< 0.01). On aspect of single symptom improvement, cough symptoms: efficiency of the treatment group was 95.00%, which of control group was 63.33%; throat itching symptoms: efficiency of the treatment group was 98.33%, which of control group was 55.00%; shortness of breath symptoms: efficiency of the treatment group was 91.67%, which of control group was 55.00%; expectoration symptoms: efficiency of the treatment group was 86.67%, which of control group was 56.67%. The differences between the two groups were all statistically significant (all P<0.05). After treatment, PEFR of treatment group [(10.41±1.45)%] was significantly lower than that of control group [(17.22±2.18)%], the difference was statistically signifi-cant (P < 0.05). The level of IL-2 in treatment group was (12.18±2.28)μg/mL, which was significantly higher than that of control group [(9.46±1.12) μg/mL], the dif-ference was highly statistically significant (P<0.01). The level of IL-6 in treatment group was (43.22±14.29) μg/mL, which was significantly lower than that of control group [(62.64±15.21) μg/mL], the difference was highly statistically significant (P< 0.01). The level of TNF-α in treatment group was (0.59±0.24) μg/mL, which was significantly lower than that of control group [(0.89±0.23)μg/mL], the difference was statistically significant (P<0.05). Conclusion Modi-fied Shashen Maidong Decoction in the treatment CVA can obviously improve clinical efficacy, which is worthy of clin-ical promotion.